| Primary |
| Acute Promyelocytic Leukaemia |
46.6% |
| Drug Use For Unknown Indication |
12.9% |
| Acute Myeloid Leukaemia |
10.4% |
| Product Used For Unknown Indication |
9.0% |
| Prophylaxis |
7.4% |
| Infection |
2.6% |
| Infection Prophylaxis |
1.8% |
| Vomiting |
1.4% |
| Acute Leukaemia |
1.2% |
| Crohn's Disease |
0.8% |
| Neutropenia |
0.8% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.8% |
| Breast Cancer |
0.6% |
| Chloasma |
0.6% |
| Disseminated Intravascular Coagulation |
0.6% |
| Pain |
0.6% |
| Pyrexia |
0.6% |
| Thrombocytopenia |
0.6% |
| Agranulocytosis |
0.4% |
| Anti-infective Therapy |
0.4% |
|
| Retinoic Acid Syndrome |
22.3% |
| Pyrexia |
7.4% |
| Respiratory Failure |
6.6% |
| Sepsis |
6.6% |
| Myelodysplastic Syndrome |
5.8% |
| Interstitial Lung Disease |
5.0% |
| Pulmonary Alveolar Haemorrhage |
5.0% |
| Renal Failure Acute |
5.0% |
| Death |
4.1% |
| Abortion Spontaneous |
3.3% |
| Alveolitis |
3.3% |
| Myalgia |
3.3% |
| Pancytopenia |
3.3% |
| Pulmonary Embolism |
3.3% |
| Respiratory Distress |
3.3% |
| Acute Myeloid Leukaemia |
2.5% |
| Liver Abscess |
2.5% |
| Nausea |
2.5% |
| Progressive Multifocal Leukoencephalopathy |
2.5% |
| Stomatitis |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
29.1% |
| Acute Promyelocytic Leukaemia |
20.4% |
| Acute Myeloid Leukaemia |
19.5% |
| Drug Use For Unknown Indication |
7.3% |
| Prophylaxis |
5.1% |
| Infection |
3.3% |
| Antiviral Prophylaxis |
1.7% |
| Retinoic Acid Syndrome |
1.7% |
| Sepsis |
1.4% |
| Disseminated Intravascular Coagulation |
1.2% |
| Pyrexia |
1.2% |
| Antifungal Prophylaxis |
1.0% |
| Aspergillosis |
1.0% |
| Vomiting |
1.0% |
| Mouth Ulceration |
0.9% |
| Myelodysplastic Syndrome |
0.9% |
| Nicotine Dependence |
0.9% |
| Antibiotic Prophylaxis |
0.7% |
| Chemotherapy |
0.7% |
| Nausea |
0.7% |
|
| Retinoic Acid Syndrome |
18.8% |
| Paraesthesia |
9.8% |
| Sepsis |
9.8% |
| Pyrexia |
8.0% |
| Pruritus Genital |
5.4% |
| Social Avoidant Behaviour |
5.4% |
| Respiratory Failure |
4.5% |
| Myositis |
3.6% |
| Osteonecrosis |
3.6% |
| Pulmonary Embolism |
3.6% |
| Type 1 Diabetes Mellitus |
3.6% |
| Abortion Spontaneous |
2.7% |
| Condition Aggravated |
2.7% |
| Flushing |
2.7% |
| Necrotising Ulcerative Gingivostomatitis |
2.7% |
| Progressive Multifocal Leukoencephalopathy |
2.7% |
| Stomatitis |
2.7% |
| Transaminases Increased |
2.7% |
| Tremor |
2.7% |
| Weight Increased |
2.7% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
15.7% |
| Acute Promyelocytic Leukaemia |
15.7% |
| Prophylaxis |
11.8% |
| Pyrexia |
10.0% |
| Product Used For Unknown Indication |
9.6% |
| Asthma |
9.2% |
| Chemotherapy |
3.1% |
| Leukaemia |
3.1% |
| Dehydration |
2.6% |
| Drug Use For Unknown Indication |
2.2% |
| Pain |
2.2% |
| Pneumocystis Jiroveci Pneumonia |
2.2% |
| Sciatica |
2.2% |
| Antiemetic Supportive Care |
1.7% |
| Gastric Ulcer |
1.7% |
| Hypertension |
1.7% |
| Alkalosis |
1.3% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Fluid Overload |
1.3% |
| Gastric Haemorrhage |
1.3% |
|
| Ventricular Fibrillation |
18.2% |
| Wound Infection Staphylococcal |
9.1% |
| Bronchitis |
6.8% |
| Transaminases Increased |
6.8% |
| Tubulointerstitial Nephritis |
6.8% |
| Diabetes Mellitus |
4.5% |
| Drug Effect Prolonged |
4.5% |
| Hyponatraemia |
4.5% |
| Neutropenia |
4.5% |
| Pancreatitis Acute |
4.5% |
| Pyrexia |
4.5% |
| Respiratory Distress |
4.5% |
| Sepsis |
4.5% |
| Cerebral Infarction |
2.3% |
| Electrocardiogram Qt Prolonged |
2.3% |
| Febrile Neutropenia |
2.3% |
| Haemorrhage |
2.3% |
| Hepatic Failure |
2.3% |
| Hepatic Function Abnormal |
2.3% |
| Leukaemia |
2.3% |
|
| Interacting |
| Acute Promyelocytic Leukaemia |
52.9% |
| Product Used For Unknown Indication |
11.8% |
| Sepsis |
11.8% |
| Fungal Infection |
5.9% |
| Infection |
5.9% |
| Nausea |
5.9% |
| Prophylaxis |
5.9% |
|
| Drug Interaction |
54.5% |
| Myositis |
18.2% |
| Hallucination, Visual |
9.1% |
| Hypercalcaemia |
9.1% |
| Vomiting |
9.1% |
|
